199172-01-5

Basic information

• Product Name: 6-BROMO-3-ETHYL-1H-INDAZOLE
• Synonyms: 6-BROMO-3-ETHYL-1H-INDAZOLE;1H-Indazole, 6-broMo-3-ethyl-
• CAS NO: 199172-01-5
• Molecular Formula: C₉H₉BrN₂
• Molecular Weight: 225.0852
• Mol File: 199172-01-5.mol

Chemical Properties

• Boiling Point: 350.923 °C at 760 mmHg
• Flash Point: 166.033 °C
• Appearance: /
• Density: 1.562 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.671
• PKA: 13.17±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-3-ETHYL-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3-ETHYL-1H-INDAZOLE(199172-01-5)
• EPA Substance Registry System: 6-BROMO-3-ETHYL-1H-INDAZOLE(199172-01-5)

Safety Data

• Hazardous Substances Data: 199172-01-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
6-BROMO-3-ETHYL-1H-INDAZOLE is used as a key intermediate in the synthesis of pharmaceuticals for its potential pharmacological properties. Its unique structure and properties make it a valuable compound for the development of new drugs and biologically active compounds.
Used in Agrochemical Research and Development:
6-BROMO-3-ETHYL-1H-INDAZOLE is also used in the research and development of agrochemicals, where its structure and properties can be explored for the creation of new compounds with potential applications in agriculture.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-BROMO-3-ETHYL-1H-INDAZOLE is utilized for its potential to contribute to the development of new drugs and biologically active compounds. Its structure can be further modified and studied to enhance its pharmacological properties and therapeutic applications.

InChI:InChI=1/C9H9BrN2/c1-2-8-7-4-3-6(10)5-9(7)12-11-8/h3-5H,2H2,1H3,(H,11,12)

Upstream product

• 13826-83-0 ammonium tetrafluroborate 
• 3355-21-3 5-Bromo-2-propyl-phenylamine 
• 67-56-1 methanol 
• 60-29-7 diethyl ether 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 1214900-59-0 1-(4-bromo-2-fluorophenyl)propan-1-ol 
• 259750-61-3 1-(4-bromo-2-fluorophenyl)propan-1-one 
• 1049651-71-9 1-(6-bromo-3-ethyl-1H-indazol-1-yl)ethanone 

Downstream Products

• 1049651-73-1 1-(4-methoxybenzyl)-6-bromo-3-ethyl-1H-indazole 
• 1300582-48-2 tert-butyl 6-bromo-3-ethyl-1H-indazole-1-carboxylate 
• 1300585-17-4 2-(1-(4-amino-3-(3-ethyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 

Relevant articles and documents

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

NOVEL KINASE MODULATORS

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds o

THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS

Therapeutically active compositions of matter are described which are useful for treating or preventing diseases and conditions comprising inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory dis

Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds of formula (I), or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal. The invention also relates to intermediates that are useful in the preparation of the compounds of formula (I).

Substituted indazole derivatives and related compounds

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R2aand R2bare independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, but not both of R2aand R2bmust be independently selected as hydrogen, wherein said substituents comprise: wherein the dashed lines in formulas (Ia) and (Ib) independently and optionally represent a single or double bond, provided that in formula (Ia) both dashed lines cannot both represent double bonds at the same time; and R, R1, R3, R4, R5, R6, R7, R18and m are as defined. The invention further relates to intermediates for the preparation of the compounds of formula I, and to pharmaceutical compositions containing, and methods of using, the compounds of formula I, or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal.

Substituted indazole derivatives and related compounds

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R2a and R2b are independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, bu

Substituted indazole analogs

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds o